Genomic Health, Inc. (NASDAQ:GHDX) COO G Bradley Cole sold 5,000 shares of the stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $30.57, for a total value of $152,850.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, July 11th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $32.53, for a total value of $162,650.00.

Shares of Genomic Health, Inc. (NASDAQ:GHDX) traded up 0.43% on Wednesday, hitting $30.52. The company had a trading volume of 67,023 shares. Genomic Health, Inc. has a 12-month low of $25.66 and a 12-month high of $33.97. The company’s market capitalization is $1.05 billion. The firm has a 50-day moving average price of $32.54 and a 200 day moving average price of $31.04.

Genomic Health (NASDAQ:GHDX) last released its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.02. The company had revenue of $85.50 million for the quarter, compared to the consensus estimate of $86.08 million. Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The business’s revenue was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.18) earnings per share. Equities analysts expect that Genomic Health, Inc. will post $0.01 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Genomic Health, Inc. (GHDX) COO G Bradley Cole Sells 5,000 Shares” was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.dailypolitical.com/2017/08/09/genomic-health-inc-ghdx-coo-g-bradley-cole-sells-5000-shares.html.

Several equities research analysts have recently weighed in on GHDX shares. Zacks Investment Research cut Genomic Health from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 18th. Raymond James Financial, Inc. reissued a “market perform” rating on shares of Genomic Health in a research report on Wednesday, May 3rd. They noted that the move was a valuation call. Jefferies Group LLC increased their price objective on Genomic Health from $29.00 to $33.00 and gave the company a “hold” rating in a research report on Wednesday, May 10th. Piper Jaffray Companies reissued a “hold” rating and issued a $31.00 price objective on shares of Genomic Health in a research report on Thursday, August 3rd. Finally, BidaskClub cut Genomic Health from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $32.43.

Several hedge funds have recently added to or reduced their stakes in GHDX. Eagle Asset Management Inc. increased its stake in Genomic Health by 0.7% in the first quarter. Eagle Asset Management Inc. now owns 320,553 shares of the medical research company’s stock worth $10,094,000 after buying an additional 2,122 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Genomic Health by 0.6% in the first quarter. Bank of New York Mellon Corp now owns 88,577 shares of the medical research company’s stock worth $2,789,000 after buying an additional 500 shares during the last quarter. Wetherby Asset Management Inc. increased its stake in Genomic Health by 4.1% in the first quarter. Wetherby Asset Management Inc. now owns 8,595 shares of the medical research company’s stock worth $271,000 after buying an additional 340 shares during the last quarter. Russell Investments Group Ltd. increased its stake in Genomic Health by 25.4% in the first quarter. Russell Investments Group Ltd. now owns 24,322 shares of the medical research company’s stock worth $766,000 after buying an additional 4,925 shares during the last quarter. Finally, Stonebridge Capital Management Inc. bought a new stake in Genomic Health during the first quarter worth $259,000. Hedge funds and other institutional investors own 89.53% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.